← ANALYST RATINGS · TIPRANKS
Tenaya Therapeutics (TNYA): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $13.00, the highest $40.00, the lowest $3.00. The average is +3,321.1% from the last price of $0.38.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.55 → $0.37−33.0% | Sell | −2.4% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.52 → $0.37−29.1% | Sell | −2.4% | Reiterated | 15.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.55 → $0.36−33.4% | Sell | −3.9% | Downgrade | 15.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.53 → $0.37−30.5% | Sell | −2.4% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.55 → $0.37−32.5% | Hold | −1.6% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.56 → $0.37−34.9% | Sell | −3.4% | Downgrade | 15.10.26on TipRanks 05:05 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $3.00 | Buy | +689.5% | Reiterated | 05.10.26on TipRanks 11:30 | −0.7%next day −3.7% · 5 days −0.2% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $5.00 | Buy | +1,215.8% | Reiterated | 06.08.26on TipRanks Aug 7 16:25 | −7.4%next day −0.5% · 5 days −0.1% | ↗ |
| Cory Jubinville, PhD★★★★★★★★★★#618 · hits 54% · avg +27.1% | LifeSci Capital | $4.00 | Buy | +952.6% | Reiterated | 06.08.26on TipRanks 15:35 | −7.4%next day −0.5% · 5 days −0.1% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $40.00 | Buy | +10,426.3% | Reiterated | 06.08.26on TipRanks 07:01 | −7.4%next day −0.5% · 5 days −0.1% | ↗ |
| Sami Corwin★★★★★★★★★★#511 · hits 55% · avg +18.5% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 03:15 | −7.4%next day −0.5% · 5 days −0.1% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $2.00 | Buy | +426.3% | Reiterated | 03.06.26on TipRanks Jun 4 06:50 | +0.1%next day −2.0% · 5 days −7.3% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $8.00 | Buy | +2,005.3% | Reiterated | 15.05.26on TipRanks 15:30 | −7.1%next day −8.6% · 5 days −10.8% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $3.00 → $2.00−33.3% | Buy | +426.3% | Reiterated | 15.12.25on TipRanks Dec 19 08:55 | −6.1%next day −3.7% · 5 days −5.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Tenaya Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $13.00 at a price of $0.56 (+2,205.0%); now: $13.00 at $0.38 (+3,321.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 12 | 14 | 9 | 7 | 5 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.10 (from $-0.14 to $-0.09). Last quarter: $-0.20.
Sales
Next quarter’s sales estimate — $1M (from $0M to $1M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Tenaya Therapeutics
- CEO: Faraz Ali
- Employees: 70
- 171 Oyster Point Boulevard, South San Francisco, CA, 94080, US
- www.tenayatherapeutics.com
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 150 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗